Bile Acid Sequestrants and the Treatment of Type 2 Diabetes Mellitus
- 285 Downloads
Bile acids promote bile formation and facilitate dietary lipid absorption. Animal and human studies showing disturbed bile acid metabolism in diabetes mellitus suggest a link between bile acids and glucose control. Bile acids are activating ligands of the farnesoid X receptor (FXR), a nuclear receptor with an established role in bile acid and lipid metabolism. Evidence suggests a role for FXR also in maintenance of glucose homeostasis. Animal and human studies employing bile acid sequestrants (bile acid binding agents), which interrupt the enterohepatic circulation of bile acids and effectively reduce plasma cholesterol, support a link between bile acid and glucose metabolism. In lipid-lowering trials, bile acid sequestrants, such as colesevelam hydrochloride, colestyramine (cholestyramine) and colestilan (colestimide), have also been shown to lower plasma glucose and glycosylated haemoglobin levels, suggesting the utility of these agents as a potential therapy for type 2 diabetes. In this article, we review the relationship between bile acid metabolism and glucose homeostasis, and present data demonstrating the utility of bile acid sequestrants in the management of diabetes.
KeywordsBile Acid Chenodeoxycholic Acid Bile Acid Synthesis Colesevelam Bile Acid Sequestrant
Bart Staels and Folkert Kuipers were supported by the EU Grant Hepadip (N° 018734). Bart Staels received additional support by a grant from the Agence Nationale de la Recherche (N° A05056GS). Editorial support was provided by Karen Stauffer, PhD and funded by Daiichi Sankyo, Inc.
- 1.International Diabetes Federation. Diabetes atlas [online]. Available from URL: http://www.eatlas.idf.org [Accessed 2006 Aug 21]
- 9.Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the Glucose-Lowering effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007; 29(1): 74–83PubMedCrossRefGoogle Scholar
- 10.Weinman SA, Kemmer N. Bile secretion and cholestasis. In: Yamada T, editor. Textbook of gastroenterology. 4th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2003: 366–88Google Scholar
- 27.Farmer JA, Gotto AM Jr. Choosing the right lipid-regulating agent. A guide to selection. Drugs 1996 Nov; 52(5): 649–61Google Scholar
- 36.Bays H, Goldberg R, Truitt K, et al. Addition of colesevelam HCl to patients with type 2 diabetes mellitus inadequately controlled on a metformin-based therapy improves glycemic control [abstract no. 204]. 16th Annual American Association of Clinical Endocrinologists Meeting and Clinical Congress; 2007 Apr 11–15; Seattle (WA), 18Google Scholar
- 37.Fonseca V, Rosenstock J, Truitt K, et al. Colesevelam HCl added to sulfonylurea-based therapy in patients with inadequately controlled type 2 diabetes mellitus improves glycemic control [abstract no. 409]. 16th Annual American Association of Clinical Endocrinologists Meeting and Clinical Congress; 2007 Apr 11–15 Seattle (WA), 10Google Scholar
- 38.Goldberg R, Truitt K. Colesevelam HCl improves glycemic control in type 2 diabetes mellitus subjects managed with insulin therapy [abstract no. 1581]. American Heart Association Scientific Sessions; 2006 Nov 12–15; Chicago (IL)Google Scholar